血浆和尿液生物标志物用于慢性肾脏病结局的系统评价与荟萃分析
该系统评价与荟萃分析检索了截至2020年11月30日的文献,纳入129项研究,评估基线血浆和尿液生物标志物与慢性肾脏病结局的关联。血浆TNFR1、FGF23、TNFR2、KIM-1和suPAR是被研究最多的标志物,其合并RR值均有统计学意义。尿液KIM-1和NGAL的合并RR值较小但仍有统计学意义。作者指出研究间存在显著异质性,限制了预后性能的比较。
要点
- 血浆TNFR1、FGF23、TNFR2、KIM-1和suPAR是被研究最多的CKD预后标志物。
- 血浆TNFR1合并RR为2.17(95%CI 1.91-2.47),TNFR2为2.07(95%CI 1.82-2.34)。
- 尿液KIM-1和NGAL的合并RR分别为1.10和1.12,效应量较小。
核心结论
- 临床前生物标志物与CKD结局的研究在研究队列和设计上存在相当大的异质性,限制了跨研究预后性能的比较。
- 血浆TNFR1、FGF23、TNFR2、KIM-1和suPAR是在CKD结局背景下被研究最多的标志物。
研究设计与样本
- 系统评价与荟萃分析,检索Embase、MEDLINE ALL和Scopus截至2020年11月30日的文献。
- 筛选26456篇摘要和352篇全文后,纳入129项研究进行随机效应荟萃分析。
主要发现
- 血浆TNFR1(31项研究)合并RR为2.17(95%CI 1.91-2.47)。
- 血浆FGF-23(30项研究)合并RR为1.21(95%CI 1.15-1.28)。
- 血浆TNFR2(23项研究)合并RR为2.07(95%CI 1.82-2.34)。
- 血浆KIM-1(18项研究)合并RR为1.51(95%CI 1.38-1.66);血浆suPAR(12项研究)合并RR为1.42(95%CI 1.30-1.55)。
- 尿液KIM-1(19项研究)合并RR为1.10(95%CI 1.05-1.16);尿液NGAL(19项研究)合并RR为1.12(95%CI 1.06-1.19)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究队列和设计存在相当大的异质性,限制了跨研究预后性能的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sensitive and specific biomarkers are needed to provide better biologic insight into the risk of incident and progressive CKD. However, studies have been limited by sample size and design heterogeneity. METHODS: In this assessment of the prognostic value of preclinical plasma and urine biomarkers for CKD outcomes, we searched Embase (Ovid), MEDLINE ALL (Ovid), and Scopus up to November 30, 2020, for studies exploring the association between baseline kidney biomarkers and CKD outcomes (incident CKD, CKD progression, or incident ESKD). We used random-effects meta-analysis. RESULTS: After screening 26,456 abstracts and 352 full-text articles, we included 129 studies in the meta-analysis for the most frequently studied plasma biomarkers (TNFR1, FGF23, TNFR2, KIM-1, suPAR, and others) and urine biomarkers (KIM-1, NGAL, and others). For the most frequently studied plasma biomarkers, pooled RRs for CKD outcomes were 2.17 (95% confidence interval [95% CI], 1.91 to 2.47) for TNFR1 (31 studies); 1.21 (95% CI, 1.15 to 1.28) for FGF-23 (30 studies); 2.07 (95% CI, 1.82 to 2.34) for TNFR2 (23 studies); 1.51 (95% CI, 1.38 to 1.66) for KIM-1 (18 studies); and 1.42 (95% CI, 1.30 to 1.55) for suPAR (12 studies). For the most frequently studied urine biomarkers, pooled RRs were 1.10 (95% CI, 1.05 to 1.16) for KIM-1 (19 studies) and 1.12 (95% CI, 1.06 to 1.19) for NGAL (19 studies). CONCLUSIONS: Studies of preclinical biomarkers for CKD outcomes have considerable heterogeneity across study cohorts and designs, limiting comparisons of prognostic performance across studies. Plasma TNFR1, FGF23, TNFR2, KIM-1, and suPAR were among the most frequently investigated in the setting of CKD outcomes.
引用
- Liu C, Debnath N, Mosoyan G, et al. Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes. J Am Soc Nephrol. 2022. PMID: 35858701. doi:10.1681/ASN.2022010098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。